Tag Archives: Prostate cancer

Pfizer Ends Sutent Trial

Successful cancer drug Sutent may not be effective in prolonging life for patients with castration-resistant prostate cancer. This week, Pfizer announced that it has ended a Phase III trial of cancer drug Sutent. The drug, which was being tested as a treatment for patients with prostate cancer, has already been approved as a treatment for […]
Posted in News | Also tagged , | 1 Comment

FDA to Review Prostate Cancer Meds

Image via Wikipedia FDA, on Monday, announced that it was reviewing whether a certain class of prostate cancer drugs could lead to diabetes, stroke, death, or heart problems. The drugs in question are gonadotropin-Releasing Hormone (GnRH) agonists, marketed under a number of monikers, including Vantas and Lupron. These treatments are used to slow the growth […]
Posted in FDA, Safety | Also tagged , , , , , , | Leave a comment

Takeda Changes Dexlansoprazole Brand Name From Kapidex to Dexilant

Takeda‘s US subsidiary launched its proton pump inhibitor dexlansoprazole last February under the name Kapidex. No one thought they’d have to find a new name a year later. But shortly after the launch, the company began getting reports of dispensing errors. Some were due to prescription misreading, others to simple, honest mistakes. The two drugs […]
Posted in Corporate Responsibility, FDA, Marketing, News, Safety, Strategy | Also tagged , , , , , , , , , | 2 Comments

Dendreon Picks Bishop as COO

Congratulations are in order for Hans Bishop, one of our 2009 emerging leaders. Dendreon just announced that it appointed Bishop chief operating officer in charge of the pending launch of the prostate cancer treatment Provenge. “Hans’ extensive and successful global commercial experience will add tremendous value to Dendreon’s already strong executive team as we prepare […]
Posted in People | Also tagged , , , , , , , | Leave a comment
  • Categories

  • Meta